4 February 2019 - - Finland-based commercial stage molecular diagnostics company Mobidiag Ltd has completed EUR 10m equity investment from Autobio Diagnostics, as announced on 18 December 2018, with receipt of all funds, the company said.

Proceeds from the EUR 10m equity investment from Autobio will be used by Mobidiag to continue growing its product portfolio, accelerate the development of further assays for the Novodiag system and enhance its manufacturing capabilities, as well as continuing to facilitate Mobidiag's commercial expansion.

The Novodiag platform is an innovative molecular diagnostics solution allowing fully automated detection of infectious diseases, including antibiotic resistances.

The platform combines real-time PCR and microarray technologies, to allow direct analysis of samples placed in a disposable cartridge.

It also allows for comprehensive screening of multiple or single pathogens within approximately one hour, allowing clinicians to be better informed when making time-critical decisions, helping to deliver early treatments and avoid the spread of infection.

Mobidiag is a commercial stage molecular diagnostics company whose technology makes the power of molecular diagnostics available to address the spread of antimicrobial resistance by rapid detection of pathogens and their potential resistance to antibiotics.

Through its Amplidiag and Novodiag solutions, Mobidiag offers a comprehensive range of fast, reliable and cost-effective molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.

Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden.

Founded in 1998, Autobio has become one of the leading clinical diagnostics companies in China. Autobio specialises in research and development, production, marketing and service of clinical diagnostic products, including immunoassay, microbiology and biochemical products.

Autobio provides comprehensive solutions for medical laboratories.